

## Call for Evidence:

# Occupational Exposure Limit for Cadmium and its Inorganic Compounds

## PART 1

## SUBMISSION OF INFORMATION ON USES AND RELATED WORKER EXPOSURE OF CADMIUM AND ITS INORGANIC COMPOUNDS

For further information, please contact:Patrick de Metz,Chairman of the Health and Safety Committee of ICdApatrick.de.metz@saftbatteries.commobile: +33 (0)6 07 11 14 08

## Table of Contents

I.	INTRODUCTION		
н.	USES OF CADMIUM AND CADMIUM COMPOUNDS		
	(1)	Main markets4	
	(2)	Use in industrial Ni-Cd batteries4	
	(3)	Use in cadmium pigments5	
III.	INTEG	RATED EXPOSURE CAPTURED BY EXPOSURE BIOMARKERS6	
	(4)	Participating companies6	
	(5)	Biomarkers6	
	(6)	Cd-U biomarker results and Interpretation7	
	(7)	Cd-U biomarker – no dilution8	
	(8)	Cd-B biomarker results and interpretation9	
	(9)	Cd-B biomarker – no dilution10	
	(10)	Conclusion on biomonitoring10	
IV.	INHALATION EXPOSURE CAPTURED BY WORKPLACE AIR MEASUREMENTS11		
	(11)	Fraction measured11	
	(12)	Same exposure groups (SEGs)11	
	(13)	Testing for compliance: the 90 <sup>th</sup> percentile11	
	(14)	SEG distribution12	
	(17)	Alternative methodology: using the geometric mean13	
	(18)	Conclusion on air monitoring14	
٧.	GENER	AL CONCLUSION ON CADMIUM MONITORING	

### I. INTRODUCTION

The International Cadmium Association (ICdA) brings together companies involved in the mining, smelting, refining, transforming, using and recycling of cadmium and compounds. A key objective of the Association is to assist members in ensuring a high level of worker protection against the adverse effects of cadmium and its compounds.

For this purpose, since 2006 ICdA has progressively roll out a program for all members consisting of three pillars:

- In 2006, ICdA has issued a detailed Guidance (the ICdA Eurometaux Guidance on the Management of the Risks related to Chronic Occupational Exposure to Cadmium and its Compounds) sharing best practice on how to reduce cadmium exposure of workers stemming from inhalation and ingestion through adequate equipment, organizational strategies as well as good hygiene practice. A series of training sessions has been deployed by ICdA through its Health and Safety Committee to assist with the proper dissemination and implementation of this Guidance,
- In 2008, the fist stage of an industry observatory was set up: the biomarker observatory ("OCdBIO") was launched,
- In 2014, a second stage followed with the creation of the air quality observatory ("OCdAIR").

The purpose of this two-pronged observatory is to document industry progress and to allow all members to benchmark their facilities with the aggregated industry performance.

This comprehensive strategy and the sustained effort of all members over the past 15 years has allowed industry to make measurable and significant progress.

ICdA is happy to share with ECHA the results of its program. The International Cadmium Association (ICdA) brings together companies involved in the mining, smelting, refining, transforming, using and recycling of cadmium and compounds. A key objective of the Association is to assist members in ensuring a high level of worker protection against the adverse effects of cadmium and its compounds.

ICdA has issued in 2006 detailed Guidance (the ICdA – Eurometaux Guidance on the Management of the Risks related to Chronic Occupational Exposure to Cadmium and its Compounds) sharing best practice on how to reduce cadmium exposure of workers stemming from inhalation and ingestion through adequate equipment, organizational as well as good hygiene strategies.

This Guidance has been updated in 2013 and 2018 to capture new scientific findings and build on employers' experience.

It has allowed industry to make regular progress over the past 15 years. This has been thoroughly documented by the Association with the help of all members.

## II. USES OF CADMIUM AND CADMIUM COMPOUNDS

#### (1) Main markets

The market for cadmium and compounds used by EU-28 industry<sup>1</sup> is estimated at 2500t, plus a net export of 900t of CdO.

The industrial sectors which have been using cadmium are rather limited and have been stable over the past years, as most uses of cadmium have been substituted. The only sectors which currently use cadmium are those for which no adequate substitute has been identified.

These uses are as follows (along with their size relative to 2500t):

_	Manufacture of industrial Ni-Cd batteries:	80%
_	Manufacture of Yellow/orange/red pigments:	12%
_	Manufacture of Cd containing alloys for neutron moderator bars, contact materials, specialty wires, brazing sticks:	4%

Thin film PV panels, frits/glass/ceramics and Infra-Red detectors: 4%

Moreover, actors involved in the manufacture of CdO export approximately 900t of this material for use outside of the EU.

#### (2) Use in industrial Ni-Cd batteries

As shown above, the largest cadmium market feeds the manufacture of industrial Ni-Cd batteries. These serve several narrow but demanding segments of the battery market.

Industrial Ni-Cd batteries withstand harsh environments (temperature, vibrations, mechanical shocks, electrical abuse) and demonstrate superior reliability and durability. These batteries can be easily monitored for aging so predictive maintenance can be conducted. Moreover, they do not suffer from the "sudden death" syndrome like Pb/acid batteries.

Based on these unique properties, they are the product of choice for back-up power of mission-critical assets, when people's lives are at stake, or when maintenance is complex and costly. Therefore, industrial Ni-Cd batteries are the reference product for commercial and military aircrafts (Airbus, Boeing and Embraer) as well as train rolling stock and underground metros. They are also the preferred solution to provide energy safety for complex assets such as nuclear power stations, oil platforms, refineries. Other uses are back-up power for trackside rail signalling systems in Scandinavian countries, for lighthouses along the North Sea coastline, for pipe and gas lines and related stations in remote areas.

Approximately 80% of EU batteries manufactured in the EU are directly or indirectly exported for use outside of Europe.

<sup>&</sup>lt;sup>1</sup>Estimation conducted in 2016, partially reassessed in 2020.

#### (3) Use in cadmium pigments

The manufacture of cadmium-based pigments in Europe is conducted by two companies only, both located in the UK.

Whereas cadmium and cadmium oxide are classified as carcinogenic, it should be noted that Cadmium zinc sulphide (yellow) and cadmium sulfo selenide (orange) pigments are not carcinogenic and are hence not regulated by CMD.

It should be noted that besides the sectors listed above in which cadmium is "used", there are several industries in which cadmium is an undesired impurity.

Based on the current participation to the biomarkers and workplace air quality observatories presented below, the workforce is split evenly between the two categories.

### III. INTEGRATED EXPOSURE CAPTURED BY EXPOSURE BIOMARKERS

ICdA has been assisting its members in providing their workforce with a healthy workplace. As part of its assistance, ICdA has been running for over a decade the Observatory of Cadmium Biomonitoring ("OCdBIO"), in which all participating companies' occupational doctors send anonymized biomonitoring data to ICdA in full compliance with RGDP, which then publishes a yearly consolidation as well as a time series across the whole EU industry.

#### (4) Participating companies

The number of industrial sites from participating companies has been growing steadily, from 15 in 2008 to 35 in the most recent 2019 reporting round. Whilst at the onset of this initiative, participating industries were essentially producers, transformers, users or recyclers of cadmium and compounds (see list of uses on previous page), companies which joined over the more recent years belong to industries in which cadmium is not voluntarily used but is rather an impurity.

#### (5) Biomarkers

Two exposure biomarkers are reported. These are urinary Cd (Cd-U) and blood Cd (Cd-B).

*Cd-U* (*Cd* concentration in urine) [expressed in  $\mu g$  *Cd/g* creatinine] is a biomarker which reflects cumulative exposure of the worker (the half-life of cadmium in the human body is commonly assumed to be in excess of 20 years). Cd-U integrates exposure from both ingestion and inhalation. There is a direct proportion between urinary clearance of cadmium and cadmium load in the kidney, which above certain levels may induce tubular dysfunction.

*Cd-B* (*Cd concentration in blood*) [*expressed in*  $\mu$ *g Cd/L whole blood*] is a biomarker which is influenced both by recent exposure (over the past 3 months) and by cumulative exposure (integrated over 20 years), arising from both ingestion and inhalation. However, the variation of Cd-B over two consecutive dates, if less than a year apart, reflects recent exposure, and its sensitivity to recent exposure (both up and down) is quite high.

#### (6) Cd-U biomarker results and Interpretation

The number of workers in excess of the biological urinary limit value recommended in many MS until 2019 (BLV: 5  $\mu$ g Cd/g creatinine) has been reduced from 121 (5.7% of the initial population) to 45 (0.9% of the final population) between 2009 to 2019.

Likewise, the number of workers in excess of the recently set BLV of 2  $\mu$ g Cd/g creatinine has been reduced from 383 (18.0% of the initial population) to 221 (4.4% of the final population) over the same 10-year time span.

Over the same 10-year period, the number of employees reporting Cd-U in OCdBIO has increased from 2125 to 4916.



It should be noted that due to the very long half-life of cadmium in the human body (estimated to be in the range of 20 years), workers with historical exposure which increased their urinary cadmium over 2  $\mu$ g Cd/g creatinine will need to be assigned to a non-exposed workplace for many years to allow for a reduction of their urinary cadmium excretion below the newly set BLV of 2  $\mu$ g Cd/g creatinine.

#### (7) Cd-U biomarker – no dilution

Due to the increasing number of participating plants over the years, a "same 15 reporting plants" statistics has been developed (see below) for Cd-U to show the evolution of Cd-U distribution over the very same 15 plants which have been participating to OCdBIO since its onset. It demonstrates that the improvement shown in the previous graph is not a statistical artefact due to dilution.



#### (8) Cd-B biomarker results and interpretation

As a marker influenced by recent exposure, the trend in Cd-B can help assess the future trend of Cd-U results. The number of workers in excess of 5  $\mu$ g Cd/L blood (the recommended not to exceed level in several MS) has been reduced from 124 (6.8% of the initial population) to 48 (1.3% of the final population) between 2009 and 2019.

Over the same 10-year period, the number of employees reporting Cd-B to OCd-BIO has increased from 1825 to 3631.



#### (9) Cd-B biomarker – no dilution

Likewise, a "same 15 reporting plants" statistics has been developed for Cd-B to show the evolution of Cd-B over the very same 15 plants (see below) which have been participating to OCdBIO since its onset. It demonstrates that the improvement shown in the previous graph is not a statistical artefact due to dilution.



#### (10) Conclusion on biomonitoring

The widespread implementation of best practice across ICdA members over the years has allowed a steady reduction of exposure which is demonstrated by exposure biomarkers, which integrate exposure from both inhalation and ingestion.

### IV. INHALATION EXPOSURE CAPTURED BY WORKPLACE AIR MEASUREMENTS

ICdA has been assisting its members in providing its workforce with a healthy workplace. As part of its assistance, ICdA has been running several years the Observatory of Cadmium Air Exposure ("OCdAIR)", in which all participating companies report to ICdA anonymous workplace air exposure information following a very strict protocol.

#### (11) Fraction measured

Building on the SCOEL conclusions of 2010 and 2017, the fraction reported to ICdA is the respirable fraction, as defined by EN 481. Equipment used to capture the respirable fraction is selected by participating companies. There are instances of companies reporting inhalable fraction data which, as it encompasses the respirable fraction and therefore yields a higher value, are taken as such in OCdAIR database and treated as respirable data.

#### (12) Same exposure groups (SEGs)

All participating plants are required to use Same Exposure Groups (SEGs) which bring together workers with a similar exposure profile.

#### (13) Testing for compliance: the 90<sup>th</sup> percentile

Compliance testing is conducted using the 90<sup>th</sup> percentile of measured values for each SEG. This 90<sup>th</sup> percentile value is calculated and **compared with the 4 \mug Cd/m<sup>3</sup> respirable fraction** which is to be considered in combination with the 2  $\mu$ g Cd/g creatinine exposure biomarker.

#### (14) SEG distribution



#### (15) Worker distribution



#### (16) Results and interpretation

The total number of workers reported to OCdAIR has been increasing over the past years from 1369 to 3379. Likewise, the number of SEGs has increased from 131 to 198.

The number of workers who belong to compliant SEGs (assessed by comparing the 90<sup>th</sup> percentile of each SEG with 4  $\mu$ g Cd/m<sup>3</sup> (respirable fraction) have risen from 483 (35% of the initial population) to 2579 (76% of the final population).

Moreover, the number of workers who belong to a SEG in excess of 10  $\mu$ g Cd/m<sup>3</sup> respirable fraction (its 90<sup>th</sup> percentile is greater than 10  $\mu$ g Cd/m<sup>3</sup> respirable fraction) has decreased from 143 individuals (10% of the initial population) to 36 individuals (1% of the final population).

#### (17) Alternative methodology: using the geometric mean

An alternative method to determine compliance of a SEG with a chronic (LT) limit value is to use the geometric mean of all measurements within that SEG for comparison purposes with the OEL. This methodology is more in line with the approach used to transform the "not to exceed 40-year long accumulated exposure in ( $\mu$ g Cd/m<sup>3</sup> · yr)" into an 8hr-TWA.

Using this alternative methodology, the number of workers in SEGs which comply with 4  $\mu$ g Cd/m<sup>3</sup> respirable fraction increases from 890 (65% of 1334) to 3241 (96% of 3361) between 2015 and 2019.



Page 13 of 14

#### (18) Conclusion on air monitoring

The data presented above demonstrate that industry has been successful in increasing the number of workers for which workplace air is regularly monitored as well as the number of workers who belong to SEGs which comply with the OEL of 4  $\mu$ g Cd/m<sup>3</sup> (respirable fraction).

Moreover, industry has been successful in almost eliminating workers who belong to SEGs with exposure above 10  $\mu$ g Cd/m<sup>3</sup> (less than 1% using the 90<sup>th</sup> percentile methodology).

#### V. GENERAL CONCLUSION ON CADMIUM MONITORING

The combination of workplace air monitoring and biomonitoring has been very effective in identifying exposure to cadmium and taking the appropriate steps to reduce such exposure and in enhancing worker protection. These results could not have been reached by implementing only air monitoring or only biomonitoring.

For further information, please contact:

Patrick de Metz, Chairman of the Health and Safety Committee of ICdA <u>patrick.de.metz@saftbatteries.com</u> mobile: +33 (0)6 07 11 14 08